Art. -Nr.: HY-B0454

Miconazole

(Synonyms: R18134)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Miconazole (R18134) is an imidazole antifungal agent that can pass through the blood-brain barrier. Miconazole also has antibacterial effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 22916-47-8
Formel: C₁₈H₁₄Cl₄N₂O
Molecular Weight:416.13

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Miconazole Chemical Structure

CAS. Nr.: 22916-47-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Miconazole (R18134) is an imidazole antifungal agent that can pass through the blood-brain barrier. Miconazole also has antibacterial effects^[1]^[2].

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Bone marrow cell	GI₅₀	12.8 μM Compound: Miconazole	Cytotoxicity against human bone marrow cells assessed as inhibition of colony formation Cytotoxicity against human bone marrow cells assessed as inhibition of colony formation	[PMID: 29549835]
HEK293	IC₅₀	6.5 μM Compound: Miconazole	Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay	[PMID: 19819046]
HEK-293T	IC₅₀	17.8 μM Compound: Miconazole	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HEK-293T	IC₅₀	6.7 μM Compound: Miconazole	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
Hepatocyte	IC₅₀	2.03 nM Compound: Miconazole	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HL-60	IC₅₀	0.8 μM Compound: Miconazole	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
J774.A1	CC₅₀	9.93 μM Compound: Miconazole	Cytotoxicity against mouse J774A1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 21385661]
J774.A1	IC₅₀	22.23 μM Compound: MCZ	Cytotoxicity against mouse J774.A1 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against mouse J774.A1 cells assessed as cell growth inhibition by MTT assay	[PMID: 37725043]
K562	CC₅₀	39.3 μM Compound: 4	Cytotoxicity to reduce chronic myeloid leukemia K 562 cells Cytotoxicity to reduce chronic myeloid leukemia K 562 cells	[PMID: 15267229]
K562	CC₅₀	80 μM Compound: 4, miconazole	Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay	[PMID: 18529046]
LLC-PK1	IC₅₀	2 μM Compound: Miconazole	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	2 μM Compound: Miconazole	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	3.5 μM Compound: Miconazole	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	3.5 μM Compound: Miconazole	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	7.8 μM Compound: Miconazole	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	7.8 μM Compound: Miconazole	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	[PMID: 12699389]
MDA-MB-231	IC₅₀	100 μM Compound: 6	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay	[PMID: 27856238]
MDA-MB-231	IC₅₀	16.96 μM Compound: Miconazole	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
MDA-MB-231	IC₅₀	27 μM Compound: 6	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba	[PMID: 27856238]
MRC5	CC₅₀	29.67 μM Compound: MC	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 20805398]
MRC5	IC₅₀	61.7 μg/mL Compound: MCZ	Cytotoxicity against human MRC5 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells incubated for 48 hrs by MTT assay	[PMID: 31191871]
NHDF	GI₅₀	10.3 μM Compound: Miconazole	Cytotoxicity against NHDF assessed as reduction in cell viability after 5 days by CellTiter-Glo assay Cytotoxicity against NHDF assessed as reduction in cell viability after 5 days by CellTiter-Glo assay	[PMID: 29549835]
PC-3	IC₅₀	13.41 μM Compound: Miconazole	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
U-937	CC₅₀	120 μM Compound: 4, miconazole	Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay	[PMID: 18529046]
U-937	CC₅₀	40 μM Compound: 4	Cytotoxicity to reduce human histolytic lymphoma U937 cells Cytotoxicity to reduce human histolytic lymphoma U937 cells	[PMID: 15267229]
Vero	CC₅₀	37.4 μM Compound: Miconazole	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23582274]

In Vitro

Miconazole is an imidazole antifungal agent, developed by Janssen Pharmaceutica, commonly applied topically to the skin or to mucous membranes to cure fungal infections. It works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. It can also be used against certain species of Leishmania protozoa which are a type of unicellular parasite that also contain ergosterol in their cell membranes. In addition to its antifungal and antiparasitic actions, it also has some antibacterial properties. Miconazole is also used in Ektachrome film developing in the final rinse of the Kodak E-6 process and similar Fuji CR-56 process, replacing formaldehyde. Fuji Hunt also includes miconazole as a final rinse additive in their formulation of the C-41RA rapid access color negative developing process. From Wikipedia.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 22916-47-8
Appearance Solid
Molecular Weight 416.13
Formel C₁₈H₁₄Cl₄N₂O
Color White to off-white
SMILES

ClC1=C(C=CC(Cl)=C1)C(OCC(C=CC(Cl)=C2)=C2Cl)CN3C=CN=C3
Synonyms

R18134
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (7)

All

Sort by:

Journal Impact Factor

Research (Wash D C)

Targeting the Exonic Circular OGT RNA/O-GlcNAc Transferase/Forkhead Box C1 Axis Inhibits Asparagine- and Alanine-Mediated Ferroptosis Repression in Neuroblastoma Progression. [Abstract]

2025 May 23:8:0703. PMID: 40416363
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Acta Physiol

The CaSR/TRPV4 coupling mediates pro-inflammatory macrophage function. [Abstract]

2023 Apr;237(4):e13926. PMID: 36606511
Chem Biol Interact

Miconazole activates MAPK-driven oligodendrogenesis to promote myelin regeneration and neurological recovery after subarachnoid hemorrhage. [Abstract]

2025 Oct 22:420:111712. PMID: 40825461
Biol Direct

Multiplex antimicrobial activities of the self-assembled amphiphilic polypeptide β nanofiber KF-5 against vaginal pathogens. [Abstract]

2024 Oct 22;19(1):96. PMID: 39438996
J Biol Chem

Capsaicin inhibits intestinal Cl- secretion and promotes Na+ absorption by blocking TRPV4 channels in healthy and colitic mice. [Abstract]

2022 May;298(5):101847. PMID: 35314195
SSRN

2026 Apr 16

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (240.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4031 mL

12.0155 mL

24.0310 mL

5 mM

0.4806 mL

2.4031 mL

4.8062 mL

10 mM

0.2403 mL

1.2015 mL

2.4031 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (5.00 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. http://en.wikipedia.org/wiki/Miconazole

[2]. Nenoff P, et al. New insights on the antibacterial efficacy of miconazole in vitro. Mycoses. 2017 Aug;60(8):552-557. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4031 mL	12.0155 mL	24.0310 mL	60.0774 mL
	5 mM	0.4806 mL	2.4031 mL	4.8062 mL	12.0155 mL
	10 mM	0.2403 mL	1.2015 mL	2.4031 mL	6.0077 mL
	15 mM	0.1602 mL	0.8010 mL	1.6021 mL	4.0052 mL
	20 mM	0.1202 mL	0.6008 mL	1.2015 mL	3.0039 mL
	25 mM	0.0961 mL	0.4806 mL	0.9612 mL	2.4031 mL
	30 mM	0.0801 mL	0.4005 mL	0.8010 mL	2.0026 mL
	40 mM	0.0601 mL	0.3004 mL	0.6008 mL	1.5019 mL
	50 mM	0.0481 mL	0.2403 mL	0.4806 mL	1.2015 mL
	60 mM	0.0401 mL	0.2003 mL	0.4005 mL	1.0013 mL
	80 mM	0.0300 mL	0.1502 mL	0.3004 mL	0.7510 mL
	100 mM	0.0240 mL	0.1202 mL	0.2403 mL	0.6008 mL

Keywords

Miconazole

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Miconazole

Anti-Infection Compound Library

FDA-Approved Drug Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

Pediatric Drug Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Miconazole

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Miconazole

Anti-Infection Compound Library

FDA-Approved Drug Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

Pediatric Drug Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Miconazole

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Miconazole Related Classifications

HY-B0454 Related Classifications